Abstract:Macrophage activation syndrome (MAS), a potentially life-threatening complication of autoimmune/autoinflammatory diseases, is characterized by the excessive expansion and activation of macrophages and cytotoxic T lymphocytes in multiple organs. Most commonly, MAS occurs in patients with systemic juvenile idiopathic arthritis and in its adult equivalent, adult-onset Still's disease (AOSD). Gasdermin D (GSDMD) is a critical pore-forming effector protein that mediates pro-inflammatory cytokine secretion via releasing its N terminal fragments to form transmembrane pores. GSDMD has been implicated in various inflammatory diseases, however, its role in MAS remains elusive. Here, we unveiled that the serum levels of GSDMD-N were elevated in patients with AOSD compared to heathy controls. In addition, the emergence of MAS features in AOSD patients resulted in further elevation. The serum levels of GSDMD were positively correlated with ferritin and interleukin-18 (IL-18). Repeated toll-like receptor 9 stimulation with unmethylated cytosine-phosphate-guanine (CpG) induced MAS symptoms in wild-type mice, including body weight loss, pancytopenia and hepatosplenomegaly. Genetic deletion and pharmacological inhibition of GSDMD ameliorated MAS symptoms in mice with the concomitant reduction of splenic and hepatic macrophage infiltration and IL-18 production. Consistent with these in vivo results, bone marrow-derived macrophages obtained from GSDMD-/- mice or treated with GSDMD inhibitor disulfiram exhibited attenuated IL-18 expression after CpG stimulation. Collectively, our findings identified GSDMD as a novel marker for MAS complication and a promising target for MAS treatment.

Author Response for "hypertonic Saccharide Solution Delays Pyroptosis in Murine Macrophages Regardless of the Membrane Binding of Gasdermin D N‐terminal"

Hypertonic saccharide solution delays pyroptosis in murine macrophages regardless of the membrane binding of gasdermin D N‐terminal

Research Progresses of Molecular Mechanism of Pyroptosis and Its Related Diseases

Inverse regulation of GSDMD and GSDME gene expression during LPS-induced pyroptosis in RAW264.7 macrophage cells

Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death

Molecular mechanism of pyroptosis and inflammasome activation

GSDMB promotes non-canonical pyroptosis by enhancing caspase-4 activity.

Genetic and Pharmacological Targeting of GSDMD Ameliorates Systemic Inflammation in Macrophage Activation Syndrome

Investigation on the Mechanism of Mafenide in Inhibiting Pyroptosis and the Release of Inflammatory Factors.

Gasdermin D in pyroptosis

Palmitoylation of gasdermin D directs its membrane translocation and pore formation in pyroptosis

Cell death and cell lysis are separable events during pyroptosis

Gasdermin D-mediated pyroptosis: mechanisms, diseases, and inhibitors

Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death

Pyroptosis inhibiting nanobodies block Gasdermin D pore formation

Gasdermin D Affects Aortic Vascular Smooth Muscle Cell Pyroptosis and Ang II-induced Vascular Remodeling

Hyperactivation of succinate dehydrogenase promotes pyroptosis of macrophage via ROS-induced GSDMD oligomerization in acute liver failure

Control of gasdermin D oligomerization and pyroptosis by the Ragulator-Rag-mTORC1 pathway

Structure Insight of GSDMD Reveals the Basis of GSDMD Autoinhibition in Cell Pyroptosis.

Mitochondrial ROS Promote Macrophage Pyroptosis by Inducing GSDMD Oxidation.

Caffeic Acid, but Not Ferulic Acid, Inhibits Macrophage Pyroptosis by Directly Blocking Gasdermin D Activation